SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced that the company has been selected as a preferred service provider for Cancer Research UK, the world’s leading cancer charity. Illumina will provide a range of services, beginning with whole human genome sequencing, in support of the International Cancer Genome Consortium. The consortium is seeking to obtain a comprehensive description of genomic, transcriptomic and epigenomic changes in 50 different tumor types and/or subtypes of clinical and societal importance.
